Back to Authors

Tanhehco, Yvette C

0000-0002-7800-3119

Mayo Clinic

Columbia University Irving Medical Center, New York, New York, USA.

Citations 2

Variation in Chronic Automated Red Cell Exchange Practices for Sickle Cell Disease: Insights Into Isovolemic Hemodilution Use
Jones, Jennifer M. , Aldarweesh, Fatima , Aqui, Nicole, Bobr, Aleh , Brunker, Patricia A. R. , Covington, Mischa L. , Guarente, Juliana , Hagar, Robert, Karafin, Matthew, Lamba, Divjot Singh , Lee, Grace M. , Mack, Ethan A. , Muthur, Gagan, Nazli, Saadiya, Olaniyan, H S, Raval, Jay S., Setya, Divya , Tanhehco, Yvette C. , Thant, Mamie, Wu, Yanyun , Wong, Edward C.C. , Zheng, Yan , Brunker, Patricia A R , Lee, Grace , Lu, Wen , Mack, Ethan A , Onyenekwu, Chinelo P , Setya, Divya , Tanhehco, Yvette C , Vivero, Angelica , Yurtsever, Nalan , Zheng, Yan , Shi, Patricia A , Webb, Jennifer , Aldarweesh, Fatima , Aqui, Nicole A., Hagar, Robert Ward, Lu, Wen , Nazli, Saadiya , Yurtsever, Nalan , Shi, Patricia A.

Journal of Clinical Apheresis | June 19, 2026 | Volume: 41 | Issue: 3 | Pages: No page available

10.1002/jca.70146 Get It

ABSTRACT Prior surveys of chronic automated red blood cell exchange (RCE) for patients with sickle cell disease (SCD) have identified considerable procedural variability, especially with the use of isovolemic hemodilution red blood cell exchange (IHD‐RCE). We conducted a survey of chronic RCE practices among American Society for Apheresis (ASFA) members to identify opportunities for practice harmonization and future studies. The ASFA SCD Research Subcommittee developed a 72‐item survey of chronic RCE practices, with a focus on IHD‐RCE. The survey was validated internally and distributed by email to all ASFA members from September 2024 to February 2025. One survey response from each institution was retained for data analysis. Descriptive statistics were performed. Sixty‐two survey responses, including three from international institutions, were retained for analysis. Sixty‐one percent of respondents (38/62) reported using at least one fixed RCE target, with end hematocrit being the most common fixed parameter (40%, 25/62), followed by fraction of cells remaining (31%, 19/62) and hemoglobin S% (27%, 17/62). Most respondents (60%, 37/61) performed IHD‐RCE at their institution, though other details such as the minimum hematocrit, exclusion criteria, and response to adverse effects were variable. Consistent pre‐ and post‐RCE laboratory monitoring practices were reported. Consistent with earlier surveys, procedural variability in chronic RCE practices for patients with SCD is observed. This highlights opportunities to compare outcomes where practice variability exists. Consensus guidelines based on institutional practices with optimal outcomes should be developed.
An Annual Review of Important Apheresis Articles in 2025 From the American Society for Apheresis Attending Physician Subcommittee
Zantek, Nicole D. , Lu, Wen , AlMozain, Nour , Lu, Wen , Almozain, Nour , Alsammak, Mohamed , Gupta, Gaurav K , Levenbrown, Yosef , Li, Yanhua , Tripathi, Parmatma Prasad , Tanhehco, Yvette C , Zantek, Nicole D , Dilly, Laura, Martin, Marisa C. Saint, Alsammak, Mohamed , Banez‐Sese, Grace, Chhibber, Vishesh, Costa, Victoria, DeChristopher, Phillip J., Durlen, Ivan , Gupta, Gaurav K. , Li, Yanhua , Mattiazzi, Adela D. , Noland, Daniel K., Prajapati, Vipulkumar, Singh, Nirupama, Siwach, Garima, Wu, Ding Wen , Wehrli, Gay , Tanhehco, Yvette C.

Journal of Clinical Apheresis | June 13, 2026 | Volume: 41 | Issue: 3 | Pages: No page available

10.1002/jca.70142 Get It

ABSTRACT Apheresis medicine is a continually evolving field with numerous studies published each year. To help apheresis practitioners stay up to date with the current literature, members of the American Society for Apheresis (ASFA) Attending Physician Subcommittee identified and summarized 10 seminal articles published in 2025, from the field of apheresis medicine. PubMed was used to identify articles published in four topics including donor apheresis, therapeutic apheresis, apheresis education, and apheresis collection for cellular therapy. These articles met at least one of the following criteria: novel findings, practice‐altering outcomes, international in scope, randomized‐controlled trial, relevant to current clinical practice, and/or provide evidence for category III or IV indications based on the ASFA 9th Special Issue of the Guidelines on the Use of Therapeutic Apheresis in Clinical Practice‐Evidence‐Based Approach. Full length, peer‐reviewed manuscripts in English with data from human subjects were included while case reports, review articles, and meta‐analyses were excluded.